Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.

Autor:	Arif S; Department of Immunobiology, King's College London, London, United Kingdom., Domingo-Vila C; Department of Immunobiology, King's College London, London, United Kingdom., Pollock E; Department of Immunobiology, King's College London, London, United Kingdom., Christakou E; Department of Immunobiology, King's College London, London, United Kingdom., Williams E; Department of Immunobiology, King's College London, London, United Kingdom., Tree TIM; Department of Immunobiology, King's College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 May 22; Vol. 14, pp. 1183909. Date of Electronic Publication: 2023 May 22 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1183909
Abstrakt:	The number of immunotherapeutic clinical trials in type 1 diabetes currently being conducted is expanding, and thus there is a need for robust immune-monitoring assays which are capable of detecting and characterizing islet specific immune responses in peripheral blood. Islet- specific T cells can serve as biomarkers and as such can guide drug selection, dosing regimens and immunological efficacy. Furthermore, these biomarkers can be utilized in patient stratification which can then benchmark suitability for participation in future clinical trials. This review focusses on the commonly used immune-monitoring techniques including multimer and antigen induced marker assays and the potential to combine these with single cell transcriptional profiling which may provide a greater understanding of the mechanisms underlying immuno-intervention. Although challenges remain around some key areas such as the need for harmonizing assays, technological advances mean that multiparametric information derived from a single sample can be used in coordinated efforts to harmonize biomarker discovery and validation. Moreover, the technologies discussed here have the potential to provide a unique insight on the effect of therapies on key players in the pathogenesis of T1D that cannot be obtained using antigen agnostic approaches. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Arif, Domingo-Vila, Pollock, Christakou, Williams and Tree.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu